Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
COMMENT
Katherine N Theken, Tilo Grosser
No abstract text is available yet for this article.
August 4, 2018: Lancet
#2
REVIEW
Dominick J Angiolillo, Fabiana Rollini, Robert F Storey, Deepak L Bhatt, Stefan James, David J Schneider, Dirk Sibbing, Derek Y F So, Dietmar Trenk, Dimitrios Alexopoulos, Paul A Gurbel, Willibald Hochholzer, Leonardo De Luca, Laurent Bonello, Daniel Aradi, Thomas Cuisset, Udaya S Tantry, Tracy Y Wang, Marco Valgimigli, Ron Waksman, Roxana Mehran, Gilles Montalescot, Francesco Franchi, Matthew J Price
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes and for those undergoing percutaneous coronary interventions. The availability of different oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) has enabled physicians to contemplate switching among therapies because of specific clinical scenarios. The recent introduction of an intravenous P2Y12 inhibitor (cangrelor) further adds to the multitude of modalities and settings in which switching therapies may occur...
November 14, 2017: Circulation
#3
JOURNAL ARTICLE
Christopher P Childers, Melinda Maggard-Gibbons, Paul G Shekelle
No abstract text is available yet for this article.
July 11, 2017: JAMA
#4
REVIEW
Simon John Wilson, David E Newby, Dana Dawson, John Irving, Colin Berry
Despite a large volume of evidence supporting the use of dual antiplatelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy. Clinical trials have varied markedly in the duration of therapy, both across and within trials. Recent systematic reviews and meta-analyses suggest that shorter durations of dual antiplatelet therapy are superior because the avoidance of atherothrombotic events is counterbalanced by the greater risks of excess major bleeding with apparent increases in all-cause mortality with longer durations...
April 2017: Heart
#5
JOURNAL ARTICLE
Glenn N Levine, Eric R Bates, John A Bittl, Ralph G Brindis, Stephan D Fihn, Lee A Fleisher, Christopher B Granger, Richard A Lange, Michael J Mack, Laura Mauri, Roxana Mehran, Debabrata Mukherjee, L Kristin Newby, Patrick T O'Gara, Marc S Sabatine, Peter K Smith, Sidney C Smith
No abstract text is available yet for this article.
September 6, 2016: Journal of the American College of Cardiology
#6
REVIEW
John A Bittl, Usman Baber, Steven M Bradley, Duminda N Wijeysundera
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after implantation of newer-generation drug-eluting stents (DES) remains uncertain. Similarly, questions remain about the role of DAPT in long-term therapy of stable post-myocardial infarction (MI) patients. AIM: Our objective was to compare the incidence of death, major hemorrhage, MI, stent thrombosis, and major adverse cardiac events in patients randomized to prolonged or short-course DAPT after implantation of newer-generation DES and in secondary prevention after MI...
September 6, 2016: Journal of the American College of Cardiology
#7
REVIEW
Glenn N Levine, Eric R Bates, John A Bittl, Ralph G Brindis, Stephan D Fihn, Lee A Fleisher, Christopher B Granger, Richard A Lange, Michael J Mack, Laura Mauri, Roxana Mehran, Debabrata Mukherjee, L Kristin Newby, Patrick T O'Gara, Marc S Sabatine, Peter K Smith, Sidney C Smith
No abstract text is available yet for this article.
September 6, 2016: Circulation
#8
RANDOMIZED CONTROLLED TRIAL
Robert F Storey, Dominick J Angiolillo, Marc P Bonaca, Mark R Thomas, Heather M Judge, Fabiana Rollini, Francesco Franchi, Arif J Ahsan, Deepak L Bhatt, Julia F Kuder, Philippe Gabriel Steg, Marc Cohen, Rangasamy Muthusamy, Eugene Braunwald, Marc S Sabatine
BACKGROUND: The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial studied 2 doses of ticagrelor, 90 mg twice a day (bid) and 60 mg bid, for long-term prevention of ischemic events in patients with prior myocardial infarction. Both doses similarly reduced the rate of ischemic events versus placebo. The pharmacokinetics and pharmacodynamics of ticagrelor 60 mg bid have not been studied...
March 15, 2016: Journal of the American College of Cardiology
#9
EDITORIAL
Marco Valgimigli, Sara Ariotti, Francesco Costa
No abstract text is available yet for this article.
May 21, 2015: European Heart Journal
#10
REVIEW
Gennaro Giustino, Usman Baber, Samantha Sartori, Roxana Mehran, Ioannis Mastoris, Annapoorna S Kini, Samin K Sharma, Stuart J Pocock, George D Dangas
BACKGROUND: The optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation is unclear, and its risks and benefits may vary according to DES generation. OBJECTIVES: The goal of this study was to evaluate the efficacy and safety of DAPT after DES implantation. METHODS: We included randomized controlled trials that tested different durations of DAPT after DES implantation: shorter dual antiplatelet therapy (S-DAPT) was defined as the per-protocol minimum duration of DAPT after the procedure, and longer dual antiplatelet therapy (L-DAPT) was defined as the per-protocol period of more prolonged DAPT...
April 7, 2015: Journal of the American College of Cardiology
#11
REVIEW
Marco Valgimigli
No abstract text is available yet for this article.
November 18, 2014: Circulation
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
